CPIX - Company ID 0001087294
The table below shows CUMBERLAND PHARMACEUTICALS INC's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Revenue | $9.13M | $13.68M | $8.29M | $10.84M | $11.71M | $10.44M |
| Cost of revenue | $1.93M | - | $988.76K | $2.01M | $1.43M | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $1.46M | - | $1.25M | $1.47M | $1.30M | - |
CUMBERLAND PHARMACEUTICALS INC reported annual revenue of $44.52M for fiscal year 2025. That is up 17.6% from $37.87M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $33.03M (FY 2016) to $44.52M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $2.55M |
| - |
| $2.57M |
| $2.87M |
| $2.46M |
| - |
| Operating income | -$3.13M | -$1.37M | -$1.97M | -$747.48K | $1.29M | -$1.84M |
| Income tax | $3.87K | - | $5.67K | $5.67K | $5.67K | - |
| Net income | -$3.29M | -$1.41M | -$1.94M | -$740.74K | $1.26M | -$1.90M |
| EPS (diluted) | -$0.22 | -$0.09 | -$0.13 | -$0.05 | $0.08 | -$0.14 |